進行性疾患に対する事前治療がなく、実用的なゲノム変化がない進行性または転移性非扁平上皮NSCLCの成人参加者を対象とした、テリソツズマブ・アジズテカンの静脈内(IV)ブディガリマブとの併用の有害事象、有効性、最適用量を評価する研究
進行性疾患に対する事前治療がなく、実用的なゲノム変化がない進行性または転移性非扁平上皮NSCLCを対象とした、ブジガリマブと併用したテリソツズマブ アジステカンの安全性、有効性、最適用量を評価する非盲検マルチコホート第1b/2相試験
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.
Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:ABBVIE CALL CENTER
- 電話番号:844-663-3742
- メール:abbvieclinicaltrials@abbvie.com
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85054
- 積極的、募集していない
- Mayo Clinic Hospital - Phoenix /ID# 272971
-
-
California
-
Fullerton、California、アメリカ、92835
- 募集
- Providence - St. Jude Medical Center /ID# 271414
-
Oxnard、California、アメリカ、93030
- 募集
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450
-
Santa Monica、California、アメリカ、90404
- 募集
- UCLA - Santa Monica /ID# 271690
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- University Of Colorado - Anschutz Medical Campus /ID# 269069
-
Lone Tree、Colorado、アメリカ、80124
- 募集
- Rocky Mountain Cancer Centers - Lone Tree /ID# 272603
-
-
Florida
-
Jacksonville、Florida、アメリカ、32224
- 募集
- Mayo Clinic Hospital Jacksonville /ID# 275073
-
Orange City、Florida、アメリカ、32763
- 募集
- Mid Florida Hematology And Oncology Center /ID# 273777
-
-
Illinois
-
Hinsdale、Illinois、アメリカ、60521
- 募集
- Hope And Healing Cancer Services /ID# 276223
-
コンタクト:
- Site Coordinator
- 電話番号:6305600121
-
-
Indiana
-
Fort Wayne、Indiana、アメリカ、46845
- 募集
- Parkview Comprehensive Cancer Center /ID# 271879
-
Indianapolis、Indiana、アメリカ、46202
- 完了
- Community Health Network /ID# 273437
-
-
Kansas
-
Overland Park、Kansas、アメリカ、66210
- 募集
- Kansas City Cancer Center /ID# 273679
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana-Farber Cancer Institute /ID# 278417
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202
- 募集
- Henry Ford Hospital - Detroit /ID# 271642
-
-
Minnesota
-
Duluth、Minnesota、アメリカ、55805
- 募集
- St. Luke'S /ID# 273344
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic-Rochester /ID# 274512
-
-
New Jersey
-
East Brunswick、New Jersey、アメリカ、08816-4096
- 募集
- Astera Cancer Care /ID# 271915
-
-
New York
-
Shirley、New York、アメリカ、11967
- 募集
- New York Cancer And Blood Specialists - Shirley /ID# 272547
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- 完了
- University Hospitals Cleveland Medical Center /ID# 271726
-
Columbus、Ohio、アメリカ、43219
- 募集
- The Mark H Zangmeister Center /ID# 272502
-
-
Pennsylvania
-
Easton、Pennsylvania、アメリカ、18045
- 募集
- Spoknwrd Clinical Trials /ID# 273776
-
コンタクト:
- Site Coordinator
- 電話番号:610-813-2087
-
-
Texas
-
Houston、Texas、アメリカ、77090
- 完了
- Millennium Physicians /ID# 271717
-
Lubbock、Texas、アメリカ、79410-1121
- 募集
- Joe Arrington Cancer Research /ID# 272776
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- 募集
- Huntsman Cancer Institute /ID# 271686
-
-
Virginia
-
Leesburg、Virginia、アメリカ、20176
- 募集
- Virgnia Cancer Specialists /ID# 269633
-
-
Washington
-
Olympia、Washington、アメリカ、98506
- 募集
- Vista Oncology - East Olympia /ID# 275438
-
Tacoma、Washington、アメリカ、98405
- 募集
- Northwest Medical Specialties Tacoma /ID# 270469
-
-
-
-
-
Buenos Aires、アルゼンチン、1426
- 募集
- Centro Oncologico Korben /ID# 281460
-
Buenos Aires、アルゼンチン、1426
- 募集
- Fundacion Respirar /ID# 281039
-
-
Buenos Aires
-
Mar del Plata、Buenos Aires、アルゼンチン、7600
- 募集
- Clinca Colon /ID# 281465
-
-
Buenos Aires F.D.
-
Ciudad Autonoma de Buenos Aire、Buenos Aires F.D.、アルゼンチン、1426
- 募集
- Instituto Alexander Fleming /ID# 282704
-
-
-
-
-
Cardiff、イギリス、CF14 2TL
- 募集
- Velindre Cancer Centre /ID# 271840
-
-
Leicestershire
-
Leicester、Leicestershire、イギリス、LE1 5WW
- 募集
- University Hospitals of Leicester NHS Trust /ID# 276035
-
-
-
-
-
Bologna、イタリア、40138
- 募集
- IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 268675
-
-
Forlì-Cesena
-
Meldola、Forlì-Cesena、イタリア、47014
- 募集
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 268684
-
-
Milano
-
Milan、Milano、イタリア、20121
- 募集
- Istituto Europeo Di Oncologia /Id# 268670
-
-
Roma
-
Rome、Roma、イタリア、00144
- 募集
- IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 268626
-
Rome、Roma、イタリア、00184
- 募集
- Azienda Ospedaliera Complesso Ospedaliero San Giovanni-Addolorata /ID# 273438
-
-
The Marches
-
Ancona、The Marches、イタリア、60126
- 募集
- Azienda Ospedaliero Universitaria delle Marche /ID# 268667
-
-
Torino
-
Orbassano、Torino、イタリア、10043
- 募集
- Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 268641
-
-
-
-
New South Wales
-
Blacktown、New South Wales、オーストラリア、2148
- 募集
- Blacktown Hospital /ID# 281588
-
-
Queensland
-
Townsville、Queensland、オーストラリア、4814
- 募集
- Townsville University Hospital /ID# 281498
-
-
South Australia
-
Elizabeth Vale、South Australia、オーストラリア、5112
- 募集
- Lyell Mcewin Hospital /ID# 281860
-
-
Victoria
-
Frankston、Victoria、オーストラリア、3199
- 募集
- Peninsula University Hospital /ID# 281824
-
-
-
-
-
A Coruña、スペイン、15006
- 募集
- Complejo Hospitalario Universitario A Coruna /ID# 271456
-
Alicante、スペイン、03010
- 募集
- Hospital General Universitario de Alicante /ID# 271316
-
Barcelona、スペイン、08036
- 募集
- Hospital Clinic de Barcelona /ID# 271452
-
Barcelona、スペイン、08041
- 募集
- Hospital Santa Creu i Sant Pau /ID# 271311
-
Barcelona、スペイン、08003
- 募集
- Hospital del Mar /ID# 271310
-
Málaga、スペイン、29010
- 募集
- Hospital Universitario Virgen de la Victoria /ID# 271312
-
-
Cantabria
-
Santander、Cantabria、スペイン、39008
- 募集
- Hospital Universitario Marques de Valdecilla /ID# 271314
-
-
Sevilla
-
Seville、Sevilla、スペイン、41009
- 募集
- Hospital Universitario Virgen Macarena /ID# 271447
-
-
-
-
Region Metropolitana Santiago
-
Santiago、Region Metropolitana Santiago、チリ、8330032
- 募集
- Pontificia Universidad Catolica De Chile /ID# 281594
-
Vitacura、Region Metropolitana Santiago、チリ、7650027
- 募集
- Oncored /Id# 281108
-
-
Santiago Metropolitan
-
Santiago、Santiago Metropolitan、チリ、6900941
- 募集
- Fundacion Arturo Lopez Perez /ID# 281211
-
Santiago、Santiago Metropolitan、チリ、7500713
- 募集
- Orlandi Oncologia /ID# 281132
-
-
-
-
-
Adana、トルコ(Türkiye)、01140
- 募集
- Adana Medical Park Seyhan Hastanesi /ID# 272875
-
Ankara、トルコ(Türkiye)、06620
- 募集
- Ankara Universitesi Tip Fakultesi Cebeci Hastanesi /ID# 272873
-
Ankara、トルコ(Türkiye)、06680
- 募集
- Liv Hospital Ankara /ID# 272876
-
Ankara、トルコ(Türkiye)、06230
- 募集
- Hacettepe Universitesi Tip Fakultesi /ID# 280631
-
Denizli、トルコ(Türkiye)、20070
- 募集
- Pamukkale Universitesi /ID# 272893
-
Istanbul、トルコ(Türkiye)、34722
- 募集
- Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi /ID# 280635
-
Konya、トルコ(Türkiye)、42080
- 募集
- Necmettin Erbakan Universitesi Meram Tip Fakultesi - Eski Hastane /ID# 272882
-
Samsun、トルコ(Türkiye)、55139
- 募集
- Ondokuz Mayis Universitesi /ID# 272899
-
Samsun、トルコ(Türkiye)、55200
- 募集
- Samsun Medical Park Hastanesi /ID# 272880
-
-
Antalya
-
Ankara、Antalya、トルコ(Türkiye)、06010
- 募集
- Gulhane Egitim ve Arastirma Hastanesi /ID# 280715
-
-
Sakarya
-
Adapazarı、Sakarya、トルコ(Türkiye)、54290
- 募集
- Sakarya Egitim ve Arastirma Hastanesi /ID# 272878
-
-
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau、Baden-Wurttemberg、ドイツ、79106
- 募集
- Universitaetsklinikum Freiburg /ID# 268473
-
Heilbronn、Baden-Wurttemberg、ドイツ、74078
- 募集
- Slk-Kliniken Heilbronn /ID# 269621
-
-
Bavaria
-
Augsburg、Bavaria、ドイツ、86150
- 募集
- Hamatologie-Onkologie im Zentrum MVZ GmbH /ID# 273043
-
Würzburg、Bavaria、ドイツ、97080
- 募集
- Universitaetsklinikum Wuerzburg /ID# 275445
-
-
Hesse
-
Frankfurt am Main、Hesse、ドイツ、60590
- 募集
- Universitaetsklinikum Frankfurt /ID# 268721
-
-
North Rhine-Westphalia
-
Cologne、North Rhine-Westphalia、ドイツ、50937
- 募集
- Universitaetsklinikum Koeln /ID# 268489
-
Hemer、North Rhine-Westphalia、ドイツ、58675
- 募集
- Lungenklinik Hemer /ID# 269779
-
-
Schleswig-Holstein
-
Oldenburg in Holstein、Schleswig-Holstein、ドイツ、23758
- 募集
- ohO Research GmbH /ID# 273060
-
-
Thuringia
-
Jena、Thuringia、ドイツ、07747
- 募集
- Universitatsklinikum Jena /ID# 269700
-
-
-
-
Gironde
-
Bordeaux、Gironde、フランス、33000
- 募集
- Institut Bergonie /ID# 258377
-
-
Loire-Atlantique
-
Saint-Herblain、Loire-Atlantique、フランス、44800
- 募集
- CHU Nantes - Hopital Laennec /ID# 268475
-
Saint-Herblain、Loire-Atlantique、フランス、44805
- 募集
- Institut de Cancerologie de l'Ouest Rene Gauducheau /ID# 268484
-
-
Occitanie
-
Montpellier、Occitanie、フランス、34070
- 募集
- Centre De Cancerologie Du Grand Montpellier /ID# 273724
-
-
Provence-Alpes-Côte d'Azur Region
-
Nice、Provence-Alpes-Côte d'Azur Region、フランス、06189
- 募集
- Centre Antoine-Lacassagne /ID# 268486
-
-
Val-de-Marne
-
Villejuif、Val-de-Marne、フランス、94805
- 募集
- Institut Gustave Roussy /ID# 258373
-
-
Île-de-France Region
-
Paris、Île-de-France Region、フランス、75248
- 募集
- Institut Curie /ID# 271395
-
-
-
-
-
Rio Piedras、プエルトリコ、00935
- 募集
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268827
-
-
-
-
-
Liège、ベルギー、4000
- 募集
- Groupe Sante CHC - Clinique du MontLegia /ID# 271760
-
-
Limburg
-
Hasselt、Limburg、ベルギー、3500
- 募集
- Jessa Ziekenhuis - Campus Virga Jesse /ID# 268573
-
-
Oost-Vlaanderen
-
Sint-Niklaas、Oost-Vlaanderen、ベルギー、9100
- 募集
- Vitaz /Id# 280187
-
-
West-Vlaanderen
-
Roeselare、West-Vlaanderen、ベルギー、8800
- 募集
- AZ-Delta. /ID# 272433
-
-
-
-
Lublin Voivodeship
-
Lublin、Lublin Voivodeship、ポーランド、20-090
- 募集
- Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie /ID# 273170
-
-
Podlaskie Voivodeship
-
Bialystok、Podlaskie Voivodeship、ポーランド、15-540
- 募集
- Uniwersytecki Szpital Kliniczny w Bialymstoku /ID# 276848
-
-
Pomeranian Voivodeship
-
Gdansk、Pomeranian Voivodeship、ポーランド、80-214
- 募集
- Uniwersyteckie Centrum Kliniczne /ID# 272418
-
-
Świętokrzyskie Voivodeship
-
Kielce、Świętokrzyskie Voivodeship、ポーランド、25-734
- 募集
- Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 274549
-
-
-
-
-
Bucharest、ルーマニア、013975
- 募集
- MNT Healthcare Europe SRL /ID# 269075
-
Bucharest、ルーマニア、030171
- 募集
- Spitalul Clinic Coltea /ID# 268726
-
Sibiu、ルーマニア、550253
- 募集
- Clinica MedLife Polisano Sibiu /ID# 269078
-
-
Cluj
-
Cluj-Napoca、Cluj、ルーマニア、400080
- 募集
- S.C. Radiotherapy Center Cluj SRL /ID# 268729
-
Cluj-Napoca、Cluj、ルーマニア、400015
- 募集
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 273125
-
Cluj-Napoca、Cluj、ルーマニア、400015
- 募集
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 268725
-
-
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100021
- 募集
- Cancer Hospital - Chinese Academy of Medical Sciences /ID# 269715
-
-
Fujian
-
Fuzhou、Fujian、中国、350014
- 募集
- Fujian Province Cancer Hospital /ID# 269150
-
-
Guangxi
-
Liuzhou、Guangxi、中国、545006
- 募集
- Liuzhou People's hospital /ID# 269667
-
-
Henan
-
Zhengzhou、Henan、中国、450008
- 募集
- Henan Cancer Hospital /ID# 269668
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- 募集
- Union Hospital - Tongji Medical College /ID# 272286
-
-
Hunan
-
Changsha、Hunan、中国、410013
- 募集
- Hunan Province Cancer Hospital /ID# 269679
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210008
- 募集
- Nanjing Drum Tower Hospital /ID# 269762
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330209
- 募集
- The First Affiliated Hospital of Nanchang University - Xianghu Campus /ID# 269190
-
-
Shaanxi
-
Xi'an、Shaanxi、中国、710061
- 募集
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271904
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200030
- 募集
- Shanghai Chest Hospital /ID# 269155
-
Shanghai、Shanghai Municipality、中国、200433
- 募集
- Shanghai Pulmonary Hospital /ID# 276397
-
-
Shanxi
-
Taiyuan、Shanxi、中国、030001
- 募集
- First Affiliated Hospital of Shanxi Medical University /ID# 276482
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- 募集
- West China Hospital of Sichuan University /ID# 270244
-
Chengdu、Sichuan、中国、610041
- 募集
- Sichuan Province Cancer Hospital /ID# 269712
-
-
Yunnan
-
Kunming、Yunnan、中国、650106
- 募集
- Yunnan Province Cancer Hospital /ID# 272331
-
-
-
-
-
Changhua、台湾、500
- 募集
- Changhua Christian Hospital /ID# 280139
-
Chiayi City、台湾、62247
- 募集
- Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation /ID# 268789
-
Kaohsiung City、台湾、807
- 募集
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 268139
-
Kaohsiung City、台湾、833
- 募集
- Kaohsiung Chang Gung Memorial Hospital /ID# 268138
-
Taipei、台湾、114
- 募集
- Tri-Service General Hospital /ID# 269211
-
Taipei、台湾、106
- 募集
- National Taiwan University Cancer Center (Ntucc) /ID# 271586
-
Taipei、台湾、112
- 募集
- Taipei Veterans General Hospital /ID# 268787
-
Taoyuan City、台湾、333
- 募集
- Linkou Chang Gung Memorial Hospital /ID# 268137
-
-
-
-
-
Nagasaki、日本、852-8501
- 募集
- Nagasaki University Hospital /ID# 273310
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、460-0001
- 募集
- NHO Nagoya Medical Center /ID# 272515
-
Nagoya、Aichi-ken、日本、464-8681
- 募集
- Aichi Cancer Center /ID# 271978
-
-
Aomori
-
Hirosaki、Aomori、日本、036-8563
- 募集
- Hirosaki University Hospital /ID# 274410
-
-
Kanagawa
-
Yokohama、Kanagawa、日本、221-0855
- 募集
- Yokohama Municipal Citizen's Hospital /ID# 271979
-
-
Kyoto
-
Kyoto、Kyoto、日本、606-8507
- 募集
- Kyoto University Hospital /ID# 272312
-
-
Niigata
-
Niigata、Niigata、日本、951-8520
- 募集
- Niigata University Medical and Dental Hospital /ID# 274448
-
-
Osaka
-
Takatsuki、Osaka、日本、569-8686
- 募集
- Osaka Medical And Pharmaceutical University Hospital /ID# 273309
-
-
Tokyo
-
Chuo-Ku、Tokyo、日本、104-0045
- 募集
- National Cancer Center Hospital /ID# 273192
-
Koto-ku、Tokyo、日本、135-8550
- 募集
- The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 271989
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study.
- Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
- For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC.
- For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration.
- Must have documented programmed death ligand 1 (PD-L1) status.
- For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization.
- Must have adequate organ function.
Exclusion Criteria:
- Known uncontrolled metastases to the central nervous system.
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1: Telisotuzumab Adizutecan + Budigalimab
Participants will receive several doses of telisotuzumab adizutecan in combination with budigalimab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
他の名前:
IV Infusion
他の名前:
|
|
実験的:Part 2 Arm 1: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose A in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
他の名前:
IV Injection IV Infusion |
|
実験的:Part 2 Arm 2: Telisotuzumab Adizutecan + Pembrolizumab
Participants will receive telisotuzumab adizutecan dose B in combination with pembrolizumab, as part of the 33 month study duration. |
Intravenous (IV) Infusion
他の名前:
IV Injection IV Infusion |
|
実験的:Part 2: Standard of Care
Participants will receive pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed, as part of the 33 month study duration. |
IV Infusion IV Infusion IV Injection IV Infusion IV Infusion |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan
時間枠:Up to Approximately 84 Days
|
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications. |
Up to Approximately 84 Days
|
|
Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
時間枠:Up to Approximately 33 Months
|
OR is defined as confirmed complete response (CR) or confirmed partial response (PR) per BICR based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Up to Approximately 33 Months
|
|
Number of Participants with Adverse Events (AE)s
時間枠:Up to Approximately 33 Months
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 33 Months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1 and Part 2: PFS as Assessed by Investigator
時間枠:Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression per Investigator based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DOR as Assessed by Investigator
時間枠:Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR per investigator to the first occurrence of radiographic progression per the investigator on RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: DC as Assessed by Investigator
時間枠:Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 11 weeks following randomization date based on RECIST v1.1, as determined by the Investigator. |
Up to Approximately 33 Months
|
|
Part 1 and Part 2: Overall Survival (OS)
時間枠:Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
Programmed Death Ligand 1 (PD-L1) and c-Met Subgroups: OR
時間枠:Up to Approximately 33 Months
|
OR is defined as confirmed CR or confirmed PR based on RECIST v1.1. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: PFS
時間枠:Up to Approximately 33 Months
|
PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression based on RECIST v1.1 or death from any cause, whichever occurs earlier. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: OS
時間枠:Up to Approximately 33 Months
|
OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DOR
時間枠:Up to Approximately 33 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR. |
Up to Approximately 33 Months
|
|
PD-L1 and c-Met Subgroups: DC
時間枠:Up to Approximately 33 Months
|
DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 12 weeks following randomization date based on RECIST v1.1. |
Up to Approximately 33 Months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:ABBVIE INC.、AbbVie
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- M24-536
- 2024-514465-18 (その他の識別子:EU CT)
- 2024-514465-18-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 共有時間枠
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 共有アクセス基準
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。